The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concernsMona Amini‐Adlé, S. Trablesi, F. Aubin et al.|Annales de Dermatologie et de Vénéréologie|2024Cited by 0